APP and Alzheimer disease: After intervention with OCYYoung‐EVs, both early stage (4‐month‐old) and later stage (6‐month‐old) APP/PS1 AD model mice exhibit improved cognitive functions and fewer Aβ plaques, more synapses, and more neurons in the brain.